BioSpace News Archive

Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions with reliable innovations that put patients at the center of care, is pleased to announce the appointment of Shaul Sharoni as the company’s new Chief Financial Officer.

Neumora Therapeutics, Inc. announced the planned initiation of the KOASTAL Program, a Phase 3 pivotal clinical program designed to evaluate the efficacy and safety of navacaprant monotherapy for the treatment of major depressive disorder.

BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, issued the following letter to shareholders.

Castle Biosciences, Inc. announced that it will host its second company-wide Castle Cares Charity Walk today, Tuesday, July 18, 2023, in Orlando, Florida.

Oxford Biomedica, a quality and innovation-led viral vector CDMO, has implemented Sapio’s Electronic Laboratory Notebook as part of its digital transformation.

PharmaTher Holdings Ltd. is pleased to announce that it has successfully completed a research study evaluating PharmaPatch™, a proprietary microneedle patch, in delivering N,N-dimethyltryptamine (“DMT”).

Advent Therapeutics, Inc. has been awarded a $3 million National Institutes of Health (NIH) Small Business Innovation Research (SBIR) Phase IIB grant.

Akebia Therapeutics today announced that Akebia completed an End of Dispute Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss Akebia’s forthcoming resubmission of its New Drug Application (NDA) for vadadustat as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on dialysis.

Eterna Therapeutics Inc. today announced the execution and closing of the sale of approximately $8.7 million aggregate principal amount of senior convertible promissory notes and accompanying warrants to purchase common stock in a private placement transaction that closed on July 14, 2023 and was priced at-the-market under Nasdaq rules.

Renibus Therapeutics, Inc. today announced raising $47 million from the initial closings of a Series B financing.